Member Info for Krone

A number of Phase 1 >$1b deals.
https://twitter.com/paras_biotech/status/1586528243498291200?s=46&t=VEsAcynvOv3y9uAJAqbVrw

As opposed to drug discovery?

Given the Sierra debacle with the anticipated return of SRA737 to CRT/ICR the operational highlights will no doubt be being redrafted to reflect the current position. One would expect Sareum to seek clarity from CRT/ICR about their intentions for the future development, or not, of SRA737 and how this may impact Sareum’s options, of which there will presumably be a number. In particular the BoD will need to carefully consider the implications on the progress of 1801/2. Whilst frustrating it must be preferable to delay the results for as long as it takes to obtain clarity and to ensure the update is robust and avoids creating further uncertainty.

https://www.pharmavoice.com/news/bristol-myers-squibb-sotyktu-psoriasis-ryan-moslin/634177/

https://www.sotyktuhcp.com/?cid=s_1932234

Spare a thought for Tim and John who have been working diligently on SRA737 for fourteen years only to spend the last 4 years being led right up the garden path by Glover and then Dilly. Tim would not have made repeated assurances of the likely progression on the basis of fresh air….he must have been fed a line by Sierra.
Moving on, I concur that the return of SRA737 may very well turn out to be a blessing in disguise not least because Sareum will have a seat at the negotiating table.

GSK Investor Relations have indicated that the next pipeline update is expected on 2 November.

C79 - another brilliant find!! Thank you.

C79 - good afternoon, all looking very positive, particularly liked the closing comment “It seems pretty clear that TYK2 inhibitors are now emerging as the next major class of anti-inflammatory therapeutics,” Byrd said. “So we’re part of a big wave.”

Hi SOG - reference to IL-6 and TYK2 JAK1 is made in one of the slides at the most recent IMC meeting,
https://www.investormeetcompany.com/investor/meeting/investor-presentation-142

Conclusions: The document provides a comprehensive consensus on the use of IL-6 inhibition to treat inflammatory disorders to inform healthcare professionals (including researchers), patients, administrators and payers.
https://pubmed.ncbi.nlm.nih.gov/35953263/

GSK has struck several multi-billion dollar deals recently under Mackay, as the company faces calls to shore up its drug pipeline after years of underperformance relative to its peers.
https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-picks-burberrys-julie-brown-cfo-2022-09-26/

Dr Keith Blundy, COO of Cancer Research Technology Limited, said: “This partnership further exemplifies CRT’s role in bringing benefit to cancer patients by forming partnerships between cancer researchers and industry to accelerate the development of new therapies. Sareum’s technologies and the expertise of The Institute will add significantly to the rate of progress of the programme.
https://www.icr.ac.uk/news-archive/major-cancer-drug-discovery-collaboration

SRA737 GSK leakage related perhaps?

https://www.bostonglobe.com/2022/09/12/business/nimbus-therapeutics-raises-125m-test-drug-psoriasis-lupus-other-diseases/

https://twitter.com/cytokineforum/status/1569363919134724097?s=46&t=cpabOj48ZRqfdJctdwYJbA

https://twitter.com/bymadeleinea/status/1569355858999447555?s=46&t=mXVxGTRYs-SI0c1hekBlwA

Noting that JR is listed as a speaker at this conference and chairing a session by Kristian Reich, Founder & Chief Scientific Officer, MoonLake Immunotherapeutics re Sonelokimab. Do we have any connections?

11.30 Spearheading a Novel Drug Candidate in Chronic
Inflammatory Skin and Joint Diseases
• Outlining the emerging story of IL-17A and F in
inflammatory diseases
• How to Optimize targeting an important cytokine
pathway - MOA and unique molecule characteristics of
the novel IL-17 drug candidate sonelokimab
• Showcasing disease control by sonelokimab from a
phase 2b trial in psoriasis
• Broadening the spectrum - Preparing for success in HS and PsA
Kristian Reich, Founder & Chief Scientific Officer, MoonLake
Immunotherapeutics

Sareum Holdings* 162.5p £110.6m (SAR.L)
The clinical stage biotech company developing next generation kinase inhibitors for autoimmune disease and cancer, notes the announcement from Bristol Myers Squibb that the US Food and Drug Administration (FDA) has approved Sotyktu™­(deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. This is the first approval by the FDA of a medicine based on TYK2, a member of the JAK cell signalling family, and therefore supports Sareum's confidence in its broader portfolio of TYK2/JAK1 inhibitors focused on autoimmune disease. Sareum has submitted a Clinical Trial Authorisation (CTA) to the UK’s Medicines and Healthcare Products Regulatory Agency to initiate a clinical trial of SDC-1801, with an initial focus on psoriasis, and hopes to begin dosing patients for Phase 1b in 2023.

Thanks WIP much appreciated!